Connecticut is currently home to 1218 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients with Sickle Cell Disease
NCT05861453
Recruiting
To assess the pharmacokinetics, pharmacodynamics and safety of Epeleuton capsules in adult SCD patients who are aged ≥18 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: New England Sickle Cell Institute, UConn Health, Farmington, Connecticut
Conditions: Sickle Cell Disease
Register for Updates
ATEMPT 2.0: Adjuvant T-DM1 Vs TH
NCT04893109
Recruiting
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1, Kadcyla) * Trastuzumab SC (Herceptin Hylecta) * Paclitaxel
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Smilow Cancer Hospital Care center at Derby, Derby, Connecticut
Conditions: Breast Cancer, HER2-positive Breast Cancer
Register for Updates
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
NCT04787042
Recruiting
This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatment, by IV infusion, and in combination with pembrolizumab. A Phase 2 monotherapy arm is also planned; the exact design of the Phase 2 study elements with respect to formulation and pre-treatment will be determined after completion of the Phase 1 study portion of the trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High
Register for Updates
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
NCT06426628
Recruiting
The goal of this observational study is to learn how a physician uses the results of the Percepta® Nasal Swab test to manage people with a newly identified pulmonary nodule. The main questions it aims to answer are: * Does the use of the Percepta Nasal swab test reduce the number of invasive procedures in people with a low-risk result and whose nodule is benign? * Does the use of the Percepta Nasal swab test decrease the time to treatment in people with a high-risk result and whose nodule is c... Read More
Gender:
ALL
Ages:
Between 29 years and 85 years
Trial Updated:
11/12/2024
Locations: Trinity Health Of New England, Hartford, Connecticut
Conditions: Pulmonary Nodule, Solitary, Lung Cancer
Register for Updates
Symptomatic Carotid Outcomes Registry
NCT05300737
Recruiting
The purpose of this study is to build upon trials done over 30 years ago, which did not include statins, new antiplatelet agents, and newer antihypertensive medications. Since the landmark trials (NASCET, ECST), there have been new developments in medical stroke prevention, which creates a gap in knowledge. The aim of this study is to evaluate that clinical care with Intensive Medical Therapy (IMT) alone, the one year stroke rate in patients with symptomatic carotid stenosis and low risk clinica... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
11/12/2024
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Carotid Stenosis, Ischemic Stroke, Transient Ischemic Attack
Register for Updates
The Rett Syndrome Global Registry
NCT04900493
Recruiting
The Rett Global Registry is a fully remote, global, caregiver-reported registry to collect information about caring for a loved one with Rett syndrome. In addition, caregivers have the ability to track and graph their loved one's symptoms and care strategies over time, store information for central access, and opt-in to complete medical record consolidation and summary. Qualified researchers and therapeutic developers may request access to de-identified aggregate information to further Rett rese... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/12/2024
Locations: Rett Syndrome Research Trust, Trumbull, Connecticut
Conditions: Rett Syndrome
Register for Updates
Oral Dronabinol-HIV
NCT06034314
Recruiting
The purpose of this study is to define the mechanisms of cannabis on the genome of people with HIV who use cannabis. The investigator aims to better understand the effect of Dronabinol on immune and inflammatory functions, and whether these changes are HIV-status dependent. This research may better inform public health policy regarding cannabis use. Depending on the results, additional studies may also build upon this research to develop more effective and specific treatments for cannabis use as... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2024
Locations: Connecticut Mental Health Center, New Haven, Connecticut
Conditions: HIV
Register for Updates
Effect of Different E-cigarette Cooling Flavors on Adults' Sensory Experience TCORS 3.0
NCT05932693
Recruiting
This pilot sensory experiment will examine cooling from comparable concentrations of WS-3 and menthol to determine appropriate concentrations to use in the main study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: E-Cig Use
Register for Updates
Enhancing Week-long Psychological Treatment for PTSD With Ketamine
NCT05737693
Recruiting
The purpose of this study is to test if the combination of ketamine, vs midazolam, with an intensive trauma-focused psychotherapy will be more effective in relieving post-traumatic stress disorder (PTSD). This week-long treatment has the potential to produce a significant therapeutic effect that otherwise would take months to occur. The study will also focus on learning about the neurophysiological changes produced by the proposed clinical trial.
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
11/08/2024
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Posttraumatic Stress Disorder
Register for Updates
SV2A in Older Adults
NCT05465538
Recruiting
The aim of the study is to examine the effect of cannabis use on brain synaptic density among older adults using \[11C\]UCB-J PET imaging.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
11/08/2024
Locations: Connecticut Mental Health Center, New Haven, Connecticut
Conditions: Cannabis Use
Register for Updates
Ketamine for the Treatment of Depression in Parkinson's Disease
NCT04944017
Recruiting
The main purpose of this study is to examine the efficacy and safety of a repeated dosing ketamine infusion paradigm compared to placebo in individuals with PD. A subset of participants in each arm will undergo baseline and post-treatment PET and fMRI scans, to examine whether changes in synaptic density and reorganization of functional networks underlie ketamine's putative antidepressant effects in PD.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
11/08/2024
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Parkinson's Disease, Depression
Register for Updates
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
NCT04797780
Recruiting
This study compares the efficacy of Tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (HR-MDS), and who have not received treatment for this diagnosis. The primary goal of the study is to compare the complete remission rate between the two treatment arms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Myelodysplastic Syndromes
Register for Updates